News & Noteworthy
BioSerenity, Inc. appoints new leadership in North America
BioSerenity, a high-growth company specializing in research and remote diagnostic solutions for neurology, sleep medicine, and cardiology, announces Jeff Wren’s appointment as Chief Executive Officer of North America. Jeff Wren assumes the leadership role in the states as Pierre Frouin, CEO of BioSerenity, moves back to Europe.
AASM Updates Protocols for MSLT & MWT
Guidance issued by AASM takes an updated look at the recommended protocols for assessing daytime sleepiness and alertness in adults. “The AASM is making a bold statement on how to handle the appropriate taper for REM-modulating or alerting or sedating compounds,” says Cairns, who is head of sleep research at BioSerenity. Read article via Sleep Review Magazine.
Premier Inc. Awards BioSerenity Preferred Partner Contract
BioSerenity has been awarded a Preferred Partner agreement with Premier GPO in the areas of sleep medicine, neurology and our SaaS platform. Premier members now have access to BioSerenity’s solutions to expand service lines and deliver high-quality, cost-effective diagnostic care. Read More.
WeHealth and BioSerenity initiate a new phase to accelerate Cardioskin
Following a successful collaboration with WeHealth™, BioSerenity is proud to announce global distribution rights of Cardioskin™. The Cardioskin™ is the only long-term connected ECG medical device that enables the acquisition, recording, storage, transmission and display of a 15-lead ECG in order to analyze potential cardiac pathological abnormalities. Read more.
BioSerenity is Awarded FDA Clearance for the new EEG Wearable Device System
Neuronaute® EEG System and IceCap® bring comprehensive Remote Electroencephalography Monitoring Services to people living with neurological disorders. Together, the IceCap® and Neuronaute® system are a unique and ideal combination to facilitate access to care in a variety of settings. Read More.
BioSerenity Develops Virtual Clinics Providing Greater Access to Care for People with Epilepsy
Healthcare access remains a challenge for people living in areas where services are overburdened due to lack of sufficient medical specialist resources. The COVID-19 pandemic places a burden on routine healthcare services in addition to changing the way physicians engage with their patients. Read More.
BioSerenity Selected by La French Tech for 2021 Next40 Class Based on Economic Performance
The French Tech Next40/120 brings together promising French companies experiencing or about to enter hypergrowth in order to support them during their hypergrowth period. By joining the French Tech Next40/120, these companies follow in the footsteps of French trailblazers such as Mirakl, Blablacar and Ynsect, to name just a few. Read More.
BioSerenity Helps Advance Understanding of COVID-19 Neurological Impact
Hospitals in France requested BioSerenity to perform EEGs in ICUs during the initial surge of Covid-19. The data was reviewed remotely by BioSerenity’s specialists and shared with medical staff. Via these collaborations, BioSerenity is one of the first to discover EEG anomalies likely associated with Covid-19. Read More.